Tectonic Therapeutic Inc. (NASDAQ: TECX) announced positive results from its Phase 1b Part B clinical trial of TX45 in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE